Upstream Bio Stock Performance
| UPB Stock | 12.76 1.93 13.14% |
The entity has a beta of 0.38, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Upstream Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Upstream Bio is expected to be smaller as well. At this point, Upstream Bio has a negative expected return of -0.47%. Please make sure to validate Upstream Bio's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if Upstream Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Upstream Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (47.18) | Five Day Return (44.69) | Year To Date Return (45.73) | Ten Year Return (33.23) | All Time Return (33.23) |
1 | What risks investors should watch in Upstream Bio Inc. stock - Insider Buying Short-Term Trading Alerts - newser.com | 11/14/2025 |
2 | Critical Review Upstream Bio Its Peers | 12/11/2025 |
3 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential - Investing.com | 12/17/2025 |
4 | Treasury Yields How Upstream Bio Inc stock reacts to global recession fears - Buy Signal Reliable Breakout Forecasts - moha.gov.vn | 12/29/2025 |
5 | Acquisition by Sutherland Everett Rand of 75000 shares of Upstream Bio subject to Rule 16b-3 | 01/02/2026 |
6 | Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
7 | Acquisition by Sutherland Everett Rand of 225000 shares of Upstream Bio at 27.07 subject to Rule 16b-3 | 01/06/2026 |
8 | Can Upstream Bio Inc outperform in the next rally - Weekly Trading Summary Long-Term Growth Stock Strategies - baoquankhu1.vn | 01/15/2026 |
9 | Upstream Bios Verekitug Study A Potential Game-Changer for Severe Asthma Treatment - MSN | 01/21/2026 |
10 | PennyMac Financial Services Q4 Earnings Call Highlights | 01/30/2026 |
11 | Pennymac Announces Acquisition of Cenlars Subservicing Business Becoming One of the Largest Mortgage Subservicers | 02/11/2026 |
| Begin Period Cash Flow | 25.8 M | |
| Total Cashflows From Investing Activities | -59.5 M |
Upstream Bio Relative Risk vs. Return Landscape
If you would invest 2,453 in Upstream Bio on November 14, 2025 and sell it today you would lose (984.00) from holding Upstream Bio or give up 40.11% of portfolio value over 90 days. Upstream Bio is generating negative expected returns assuming volatility of 7.6435% on return distribution over 90 days investment horizon. In other words, 68% of stocks are less volatile than Upstream, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Upstream Bio Target Price Odds to finish over Current Price
The tendency of Upstream Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.76 | 90 days | 12.76 | close to 99 |
Based on a normal probability distribution, the odds of Upstream Bio to move above the current price in 90 days from now is close to 99 (This Upstream Bio probability density function shows the probability of Upstream Stock to fall within a particular range of prices over 90 days) .
Upstream Bio Price Density |
| Price |
Predictive Modules for Upstream Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Upstream Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Upstream Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Upstream Bio is not an exception. The market had few large corrections towards the Upstream Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Upstream Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Upstream Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.42 | |
β | Beta against Dow Jones | 0.38 | |
σ | Overall volatility | 3.00 | |
Ir | Information ratio | -0.06 |
Upstream Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Upstream Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Upstream Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Upstream Bio generated a negative expected return over the last 90 days | |
| Upstream Bio has high historical volatility and very poor performance | |
| Upstream Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 2.37 M. Reported Net Loss for the year was (62.81 M) with profit before taxes, overhead, and interest of 2.8 M. | |
| Upstream Bio generates negative cash flow from operations | |
| Over 93.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Pennymac Announces Acquisition of Cenlars Subservicing Business Becoming One of the Largest Mortgage Subservicers |
Upstream Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Upstream Stock often depends not only on the future outlook of the current and potential Upstream Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Upstream Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.3 M | |
| Cash And Short Term Investments | 470.5 M |
Upstream Bio Fundamentals Growth
Upstream Stock prices reflect investors' perceptions of the future prospects and financial health of Upstream Bio, and Upstream Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Upstream Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (55.39) % | ||||
| Current Valuation | 1.13 B | ||||
| Shares Outstanding | 54.04 M | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 536.91 X | ||||
| Revenue | 2.37 M | ||||
| Gross Profit | 2.8 M | ||||
| EBITDA | (77.67 M) | ||||
| Net Income | (62.81 M) | ||||
| Total Debt | 1.83 M | ||||
| Book Value Per Share | 7.01 X | ||||
| Cash Flow From Operations | (59.17 M) | ||||
| Earnings Per Share | (6.40) X | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 481.72 M | ||||
| Retained Earnings | (190.78 M) | ||||
| Working Capital | 468.42 M | ||||
About Upstream Bio Performance
By analyzing Upstream Bio's fundamental ratios, stakeholders can gain valuable insights into Upstream Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Upstream Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Upstream Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.12) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.13) | (0.15) |
Things to note about Upstream Bio performance evaluation
Checking the ongoing alerts about Upstream Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Upstream Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Upstream Bio generated a negative expected return over the last 90 days | |
| Upstream Bio has high historical volatility and very poor performance | |
| Upstream Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 2.37 M. Reported Net Loss for the year was (62.81 M) with profit before taxes, overhead, and interest of 2.8 M. | |
| Upstream Bio generates negative cash flow from operations | |
| Over 93.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Pennymac Announces Acquisition of Cenlars Subservicing Business Becoming One of the Largest Mortgage Subservicers |
- Analyzing Upstream Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Upstream Bio's stock is overvalued or undervalued compared to its peers.
- Examining Upstream Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Upstream Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Upstream Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Upstream Bio's stock. These opinions can provide insight into Upstream Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Upstream Stock analysis
When running Upstream Bio's price analysis, check to measure Upstream Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio is operating at the current time. Most of Upstream Bio's value examination focuses on studying past and present price action to predict the probability of Upstream Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio's price. Additionally, you may evaluate how the addition of Upstream Bio to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |